Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,873 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).
Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, Kato T, Ohta H, Iwasawa Y. Kawamoto H, et al. Among authors: nakashima h. J Med Chem. 1999 Dec 16;42(25):5061-3. doi: 10.1021/jm990517p. J Med Chem. 1999. PMID: 10602690 No abstract available.
2-Cyclohexylcarbonylbenzimidazoles as potent, orally available and brain-penetrable opioid receptor-like 1 (ORL1) antagonists.
Kobayashi K, Uchiyama M, Takahashi H, Kawamoto H, Ito S, Yoshizumi T, Nakashima H, Kato T, Shimizu A, Yamamoto I, Asai M, Miyazoe H, Ohno A, Hirayama M, Ozaki S, Tani T, Ishii Y, Tanaka T, Mochidome T, Tadano K, Fukuroda T, Ohta H, Okamoto O. Kobayashi K, et al. Among authors: nakashima h. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3096-9. doi: 10.1016/j.bmcl.2009.04.023. Epub 2009 Apr 11. Bioorg Med Chem Lett. 2009. PMID: 19394217
Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate.
Satoh A, Sagara T, Sakoh H, Hashimoto M, Nakashima H, Kato T, Goto Y, Mizutani S, Azuma-Kanoh T, Tani T, Okuda S, Okamoto O, Ozaki S, Iwasawa Y, Ohta H, Kawamoto H. Satoh A, et al. Among authors: nakashima h. J Med Chem. 2009 Jul 23;52(14):4091-4. doi: 10.1021/jm900581g. J Med Chem. 2009. PMID: 19537798
Obesity Is Associated with Asymptomatic Vertebral Fractures: A Yakumo Study.
Miyairi Y, Nakashima H, Ito S, Segi N, Ouchida J, Oishi R, Yamauchi I, Machino M, Seki T, Ishizuka S, Takegami Y, Hasegawa Y, Imagama S. Miyairi Y, et al. Among authors: nakashima h. J Clin Med. 2024 Apr 2;13(7):2063. doi: 10.3390/jcm13072063. J Clin Med. 2024. PMID: 38610830 Free PMC article.
Effects of CD34+ cell dose on engraftment and long-term outcomes after allogeneic bone marrow transplantation.
Oyama T, Fujiwara SI, Tominaga R, Yokoyama D, Noguchi A, Furuki S, Koyama S, Murahashi R, Nakashima H, Hyodo K, Ikeda T, Kawaguchi SI, Toda Y, Nagayama T, Umino K, Minakata D, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Otsuki I, Ohmine K, Kanda Y. Oyama T, et al. Among authors: nakashima h. Clin Transplant. 2024 Apr;38(4):e15313. doi: 10.1111/ctr.15313. Clin Transplant. 2024. PMID: 38581299
1,873 results